SCHEMBL329515

SCHEMBL329515

c1cc2c(cc1OCCCN1CCOCC1)CNC2

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.73
HTR2A P28223 4/20 0.59
KCNH2 Q12809 4/20 0.59
MAPK1 P28482 2/20 0.59
ALDH1A1 P00352 2/20 0.59
CYP1A2 P05177 1/20 0.59
CHRM2 P08172 1/20 0.59
CHRM1 P11229 1/20 0.59
SCN1A P35498 1/20 0.59
HTR2B P41595 1/20 0.59
SCN2A Q99250 1/20 0.59
SIGMAR1 Q99720 1/20 0.59
SCN3A Q9NY46 1/20 0.59
HTR1A P08908 3/20 0.58
DRD2 P14416 3/20 0.58
USP2 O75604 1/20 0.58
LMNA P02545 1/20 0.58
HRH1 P35367 2/20 0.54
KDM4E B2RXH2 1/20 0.52
HRH2 P25021 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29640958 0.93 HRH3 (0.63) HRH3HTR2AKCNH2MAPK1ALDH1A1
SCHEMBL329891 0.93 HRH3 (0.63) HRH3HTR2AKCNH2MAPK1ALDH1A1
Hydrochloric Acid SCHEMBL31014160 0.92 HRH3 (0.62) HRH3HTR2AKCNH2MAPK1ALDH1A1
SCHEMBL12853690 0.81 HRH3 (0.65) HRH3HTR2AKCNH2MAPK1ALDH1A1
SCHEMBL19339145 0.80 HRH3 (0.64) HRH3HTR2AKCNH2MAPK1ALDH1A1
Hydrochloric Acid SCHEMBL31014123 0.78 MEN1 (0.57) HRH3HTR2AKCNH2MAPK1ALDH1A1
SCHEMBL14232256 0.78 SMN1; SMN2 (0.49) HRH3MAPK1ALDH1A1USP2KDM4E
SCHEMBL4727335 0.77 DRD2 (0.73) HRH3HTR2AKCNH2HTR1ADRD2
SCHEMBL14287578 0.76 HRH3 (1.00) HRH3HRH1
SCHEMBL14287568 0.76 HRH3 (1.00) HRH3HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9914719-B2 Hydroxybenzamide derivatives and their use as inhibitors of HSP90 ASTEX THERAPEUTICS LTD. (GB) 2018-03-13 US disclosed
US-9730912-B2 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED (GB) 2017-08-15 US disclosed
EP-1680137-B1 Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication HOFFMANN LA ROCHE (CH) 2012-11-21 EP disclosed
EP-2407470-A2 Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication F. Hoffmann-La Roche Ltd. (CH) 2012-01-18 EP disclosed
US-20090286843-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION HOFFMANN-LA ROCHE INC. 2009-11-19 US disclosed
US-20090111982-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION HOFFMANN-LA ROCHE INC. 2009-04-30 US disclosed
US-20090111969-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION HOFFMANN-LA ROCHE INC. 2009-04-30 US disclosed
US-20090105471-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION HOFFMANN-LA ROCHE INC. 2009-04-23 US disclosed
US-7491794-B2 Macrocyclic compounds as inhibitors of viral replication INTERMUNE, INC. (US) 2009-02-17 US disclosed
WO-2008044027-A2 PHARMACEUTICAL COMPOUNDS HAVING HSP90 INHIBITORY OR MODULATING ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2008-04-17 WO disclosed
EP-1680137-A2 MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION Intermune, Inc. (US) 2006-07-19 EP disclosed
US-20050267018-A1 Macrocyclic compounds as inhibitors of viral replication HOFFMANN-LA ROCHE INC. 2005-12-01 US disclosed
WO-2005037214-A2 MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION INTERMUNE, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111982-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, ZC3HAV1 HRH3 4394/4885HTR2A 4550/4885KCNH2 2713/4885
US-20090286843-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, ZC3HAV1 HRH3 4394/4885HTR2A 4550/4885KCNH2 2713/4885
US-20090111969-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, ZC3HAV1 HRH3 4394/4885HTR2A 4550/4885KCNH2 2713/4885
US-20050267018-A1 Macrocyclic compounds as inhibitors of viral replication EIF2AK2, HAVCR2, ZC3HAV1 HRH3 4394/4885HTR2A 4550/4885KCNH2 2713/4885
US-20090105471-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, ZC3HAV1 HRH3 4394/4885HTR2A 4550/4885KCNH2 2713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.